Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA.
A.J. Drexel Autism Institute, Drexel University, Philadelphia, PA.
J Glaucoma. 2023 Sep 1;32(9):738-743. doi: 10.1097/IJG.0000000000002271. Epub 2023 Jul 20.
This retrospective study found a statistically significant reduction in mean intraocular pressure (IOP) and the number of medications after intracameral Bimatoprost sustained release (SR) injection in patients with glaucoma. A history of selective laser trabeculoplasty (SLT) did not impact treatment outcomes.
To determine outcomes of Bimatoprost SR on IOP and the number of topical IOP-lowering medications in patients with glaucoma. A secondary objective was to determine the outcomes of Bimatoprost SR in patients with a prior history of SLT.
Retrospective case series. One hundred eighteen eyes from 84 patients that received Bimatoprost SR by 6 glaucoma specialists at Wills Eye Hospital from March 2020 to September 2021 were examined. The intervention was a single injection of intracameral Bimatoprost SR. The main outcome measures included IOP and the number of medications.
The most recent mean follow-up time for all eyes was 27.8 ± 18.6 weeks. The mean posttreatment IOP at the most recent follow-up of 16.6 ± 5.3 mm Hg was significantly lower than the mean under-therapy pretreatment IOP of 18.5 ± 5.7 mm Hg for all eyes ( P < 0.01). The mean posttreatment number of medications at the most recent follow-up of 1.3 ± 1.3 decreased compared with the number of pretreatment medications of 2.1 ± 1.4 for all eyes ( P < 0.01). Analysis of multilevel models controlling for demographic variables demonstrated a statistically significant reduction in IOP and number of medications posttreatment ( P < 0.01). A prior history of SLT (n = 54) had no impact on treatment for both IOP and the number of medications ( P > 0.1 for both).
Intracameral Bimatoprost SR reduced IOP and decreased the number of medications. Prior history of SLT did not impact Bimatoprost SR treatment outcomes.
本回顾性研究发现，在青光眼患者中，单次房水内注射比马前列素持续释放（SR）后，平均眼内压（IOP）和用药数量均有统计学显著降低。选择性激光小梁成形术（SLT）史并不影响治疗结果。
确定比马前列素 SR 对青光眼患者 IOP 和降眼压药物数量的影响。次要目的是确定比马前列素 SR 在 SLT 史患者中的治疗效果。
回顾性病例系列研究。2020 年 3 月至 2021 年 9 月，威尔斯眼科医院的 6 位青光眼专家对 84 例患者的 118 只眼进行了比马前列素 SR 治疗。干预措施为单次房水内注射比马前列素 SR。主要观察指标包括 IOP 和药物数量。
所有患者的最近平均随访时间为 27.8±18.6 周。所有患者最近随访时的平均治疗后 IOP 为 16.6±5.3mmHg，显著低于治疗前的平均 IOP 18.5±5.7mmHg（P＜0.01）。所有患者最近随访时的平均治疗后药物数量为 1.3±1.3，与治疗前的药物数量 2.1±1.4 相比有所减少（P＜0.01）。控制人口统计学变量的多水平模型分析显示，治疗后 IOP 和药物数量均有统计学显著降低（P＜0.01）。既往 SLT 史（n=54）对 IOP 和药物数量均无影响（两者均 P＞0.1）。
房水内注射比马前列素 SR 可降低 IOP 和减少用药数量。既往 SLT 史不影响比马前列素 SR 的治疗效果。
